Incyte posts 24-week TRuE-AD4 data on long-term safety of ruxolitinib cream in moderate atopic dermatitis at EADV 2026
INCY•Prurigo nodularis studies
Additional studies outline market and utilization dynamics in prurigo nodularis, including prevalence, treatment patterns, and healthcare resource use in the US and Germany.
Povorcitinib analyses in hidradenitis suppurativa
Povorcitinib Phase 3 analyses in hidradenitis suppurativa highlight improvements across clinical outcomes, patient-reported burden, and biomarkers in higher-burden patients.
Incyte highlights inflammation and autoimmunity data at EADV 2026
Incyte flagged new clinical and real-world data across its inflammation and autoimmunity portfolio for presentation at EADV 2026 in Vienna.
Key readouts center on ruxolitinib cream in moderate atopic dermatitis, including longer-term safety, patient-reported benefits, and reduced need to escalate therapy.
